SARS-CoV-2 Infection in the Follow-Up of a Population With Inflammatory Bowel Disease
- PMID: 35191988
- PMCID: PMC9383483
- DOI: 10.1093/ibd/izac005
SARS-CoV-2 Infection in the Follow-Up of a Population With Inflammatory Bowel Disease
Comment on
-
COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.Inflamm Bowel Dis. 2022 Aug 1;28(8):1265-1279. doi: 10.1093/ibd/izab236. Inflamm Bowel Dis. 2022. PMID: 34718595 Free PMC article.
References
-
- Gilissen LPL, Heinen SGH, Rijpma-Jacobs L, et al. . Neither inflammatory bowel disease nor immunosuppressants are associated with an increased risk of severe COVID-19: an observational Dutch cohort study. Clin Exp Med. Published online September 20, 2021. doi:10.1007/s10238-021-00755-3 - DOI - PMC - PubMed
-
- Kennedy NA, Lin S, Goodhand JR, et al. .; Contributors to the CLARITY IBD study. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021;70:1884-1893. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
